| Year |
Citation |
Score |
| 2024 |
Morez M, Lara Ordóñez AJ, Melnyk P, Liberelle M, Lebègue N, Taymans JM. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date. Expert Opinion On Therapeutic Patents. 34: 773-788. PMID 39023243 DOI: 10.1080/13543776.2024.2378076 |
0.554 |
|
| 2024 |
Naaldijk Y, Fernández B, Fasiczka R, Fdez E, Leghay C, Croitoru I, Kwok JB, Boulesnane Y, Vizeneux A, Mutez E, Calvez C, Destée A, Taymans JM, Aragon AV, Yarza AB, et al. A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells. Npj Parkinson's Disease. 10: 12. PMID 38191886 DOI: 10.1038/s41531-023-00624-8 |
0.691 |
|
| 2023 |
Iannotta L, Emanuele M, Favetta G, Tombesi G, Vandewynckel L, Lara Ordóñez AJ, Saliou JM, Drouyer M, Sibran W, Civiero L, Nichols RJ, Athanasopoulos PS, Kortholt A, Chartier-Harlin MC, Greggio E, ... Taymans JM, et al. PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formation. Frontiers in Molecular Neuroscience. 16: 1269387. PMID 38169846 DOI: 10.3389/fnmol.2023.1269387 |
0.713 |
|
| 2023 |
Taymans JM, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, Peter I, Rideout H, Thaler A. Perspective on the current state of the LRRK2 field. Npj Parkinson's Disease. 9: 104. PMID 37393318 DOI: 10.1038/s41531-023-00544-7 |
0.355 |
|
| 2023 |
Filippini F, Nola S, Zahraoui A, Roger K, Esmaili M, Sun J, Wojnacki J, Vlieghe A, Bun P, Blanchon S, Rain JC, Taymans JM, Chartier-Harlin MC, Guerrera C, Galli T. Secretion of VGF relies on the interplay between LRRK2 and post-Golgi v-SNAREs. Cell Reports. 42: 112221. PMID 36905628 DOI: 10.1016/j.celrep.2023.112221 |
0.612 |
|
| 2023 |
Taymans JM, Mutez E, Sibran W, Vandewynckel L, Deldycke C, Bleuse S, Marchand A, Sarchione A, Leghay C, Kreisler A, Simonin C, Koprich J, Baille G, Defebvre L, Dujardin K, et al. Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson's disease and pharmacodynamic biomarkers. Npj Parkinson's Disease. 9: 21. PMID 36750568 DOI: 10.1038/s41531-023-00445-9 |
0.706 |
|
| 2022 |
Coku I, Mutez E, Eddarkaoui S, Carrier S, Marchand A, Deldycke C, Goveas L, Baille G, Tir M, Magnez R, Thuru X, Vermeersch G, Vandenberghe W, Buée L, Defebvre L, ... ... Taymans JM, et al. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 35708213 DOI: 10.1002/mds.29124 |
0.613 |
|
| 2022 |
Marchand A, Sarchione A, Athanasopoulos PS, Roy HB, Goveas L, Magnez R, Drouyer M, Emanuele M, Ho FY, Liberelle M, Melnyk P, Lebègue N, Thuru X, Nichols RJ, Greggio E, ... ... Taymans JM, et al. A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively. Cells. 11. PMID 35326469 DOI: 10.3390/cells11061018 |
0.71 |
|
| 2022 |
Cogo S, Ho FY, Tosoni E, Tomkins JE, Tessari I, Iannotta L, Montine TJ, Manzoni C, Lewis PA, Bubacco L, Chartier Harlin MC, Taymans JM, Kortholt A, Nichols J, Cendron L, et al. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Brain Research. 147781. PMID 35016853 DOI: 10.1016/j.brainres.2022.147781 |
0.58 |
|
| 2021 |
Sarchione A, Marchand A, Taymans JM, Chartier-Harlin MC. Alpha-Synuclein and Lipids: The Elephant in the Room? Cells. 10. PMID 34572099 DOI: 10.3390/cells10092452 |
0.578 |
|
| 2021 |
Cresto N, Gardier C, Gaillard MC, Gubinelli F, Roost P, Molina D, Josephine C, Dufour N, Auregan G, Guillermier M, Bernier S, Jan C, Gipchtein P, Hantraye P, Chartier-Harlin MC, ... ... Taymans JM, et al. The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo. International Journal of Molecular Sciences. 22. PMID 34201785 DOI: 10.3390/ijms22136760 |
0.605 |
|
| 2021 |
Drouyer M, Bolliger MF, Lobbestael E, Van den Haute C, Emanuele M, Lefebvre R, Sibran W, De Wit T, Leghay C, Mutez E, Dzamko N, Halliday GM, Murayama S, Martoriati A, Cailliau K, ... ... Taymans JM, et al. Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. Neurobiology of Disease. 105426. PMID 34144124 DOI: 10.1016/j.nbd.2021.105426 |
0.733 |
|
| 2021 |
Goveas L, Mutez E, Chartier-Harlin MC, Taymans JM. Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells. Cells. 10. PMID 33922322 DOI: 10.3390/cells10050981 |
0.625 |
|
| 2020 |
Rideout HJ, Chartier-Harlin MC, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CEG, Mabrouk OS, Taymans JM. The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease. Frontiers in Neuroscience. 14: 865. PMID 33013290 DOI: 10.3389/Fnins.2020.00865 |
0.667 |
|
| 2020 |
Lobbestael E, Van den Haute C, Macchi F, Taymans JM, Baekelandt V. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity. Bioscience Reports. 40. PMID 32975566 DOI: 10.1042/BSR20202225 |
0.466 |
|
| 2020 |
Marchand A, Drouyer M, Sarchione A, Chartier-Harlin MC, Taymans JM. LRRK2 Phosphorylation, More Than an Epiphenomenon. Frontiers in Neuroscience. 14: 527. PMID 32612495 DOI: 10.3389/Fnins.2020.00527 |
0.735 |
|
| 2019 |
Fernández B, Lara Ordóñez AJ, Fdez E, Mutez E, Comptdaer T, Leghay C, Kreisler A, Simonin C, Vandewynckel L, Defebvre L, Destée A, Bleuse S, Taymans JM, Chartier-Harlin MC, Hilfiker S. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients. The Biochemical Journal. PMID 31527116 DOI: 10.1042/Bcj20190315 |
0.703 |
|
| 2018 |
Taymans JM, Chartier-Harlin MC. In silico and Wet Bench Interactomics Sheds Light on the Similitudes and Differences between Human ROCO Proteins. Proteomics. e1800103. PMID 29791783 DOI: 10.1002/Pmic.201800103 |
0.572 |
|
| 2018 |
Madero-Pérez J, Fdez E, Fernández B, Lara Ordóñez AJ, Blanca Ramírez M, Gómez-Suaga P, Waschbüsch D, Lobbestael E, Baekelandt V, Nairn AC, Ruiz-Martínez J, Aiastui A, López de Munain A, Lis P, Comptdaer T, ... Taymans JM, et al. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. Molecular Neurodegeneration. 13: 3. PMID 29357897 DOI: 10.1186/S13024-018-0235-Y |
0.729 |
|
| 2017 |
Civiero L, Cogo S, Kiekens A, Morganti C, Tessari I, Lobbestael E, Baekelandt V, Taymans JM, Chartier-Harlin MC, Franchin C, Arrigoni G, Lewis PA, Piccoli G, Bubacco L, Cookson MR, et al. PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2. Frontiers in Molecular Neuroscience. 10: 417. PMID 29311810 DOI: 10.3389/Fnmol.2017.00417 |
0.724 |
|
| 2017 |
Sejwal K, Chami M, Rémigy H, Vancraenenbroeck R, Sibran W, Sütterlin R, Baumgartner P, McLeod R, Chartier-Harlin MC, Baekelandt V, Stahlberg H, Taymans JM. Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. Scientific Reports. 7: 8667. PMID 28819229 DOI: 10.1038/S41598-017-09126-Z |
0.673 |
|
| 2017 |
Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, Frassineti M, Masala A, Esposito S, Galioto M, Valle C, Carri MT, Biosa A, Greggio E, Crosio C, et al. Role of LRRK2 in the regulation of dopamine receptor trafficking. Plos One. 12: e0179082. PMID 28582422 DOI: 10.1371/Journal.Pone.0179082 |
0.363 |
|
| 2017 |
Ramírez MB, Ordóñez AJL, Fdez E, Madero-Pérez J, Gonnelli A, Drouyer M, Chartier-Harlin MC, Taymans JM, Bubacco L, Greggio E, Hilfiker S. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. Human Molecular Genetics. 26: 2747-2767. PMID 28453723 DOI: 10.1093/Hmg/Ddx161 |
0.708 |
|
| 2017 |
Taymans JM. Regulation of LRRK2 by Phosphatases. Advances in Neurobiology. 14: 145-160. PMID 28353283 DOI: 10.1007/978-3-319-49969-7_8 |
0.485 |
|
| 2017 |
Taymans JM, Mutez E, Drouyer M, Sibran W, Chartier-Harlin MC. LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker? Biochemical Society Transactions. 45: 207-212. PMID 28202674 DOI: 10.1042/Bst20160334 |
0.726 |
|
| 2017 |
Lobbestael E, Civiero L, De Wit T, Taymans J, Greggio E, Baekelandt V. LRRK2 kinase inhibition, a potential Parkinson’s disease therapy, induces LRRK2 protein destabilization and proteasomal degradation Frontiers in Neuroscience. 11. DOI: 10.3389/conf.fnins.2017.94.00100 |
0.406 |
|
| 2017 |
Wit TD, Lobbestael E, Böllliger M, Drouyer M, Chartier-Harlin M, Nichols RJ, Taymans J, Baekelandt V. Phosphatome-wide siRNA screen reveals phosphorylation regulators of the Parkinson’s disease protein LRRK2. Frontiers in Neuroscience. 11. DOI: 10.3389/Conf.Fnins.2017.94.00094 |
0.634 |
|
| 2016 |
Lobbestael E, Civiero L, De Wit T, Taymans JM, Greggio E, Baekelandt V. Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation. Scientific Reports. 6: 33897. PMID 27658356 DOI: 10.1038/srep33897 |
0.549 |
|
| 2016 |
Taymans JM, Greggio E. LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? Current Neuropharmacology. 14: 214-25. PMID 26517051 DOI: 10.2174/1570159x13666151030102847 |
0.484 |
|
| 2015 |
Civiero L, Cirnaru MD, Beilina A, Rodella U, Russo I, Belluzzi E, Lobbestael E, Reyniers L, Hondhamuni G, Lewis PA, Van den Haute C, Baekelandt V, Bandopadhyay R, Bubacco L, Piccoli G, ... ... Taymans JM, et al. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain. Journal of Neurochemistry. PMID 26375402 DOI: 10.1111/Jnc.13369 |
0.52 |
|
| 2015 |
Taymans JM, Nkiliza A, Chartier-Harlin MC. Deregulation of protein translation control, a potential game-changing hypothesis for Parkinson's disease pathogenesis Trends in Molecular Medicine. 21: 466-472. PMID 26091824 DOI: 10.1016/J.Molmed.2015.05.004 |
0.673 |
|
| 2015 |
Krumova P, Reyniers L, Meyer M, Lobbestael E, Stauffer D, Gerrits B, Muller L, Hoving S, Kaupmann K, Voshol J, Fabbro D, Bauer A, Rovelli G, Taymans JM, Bouwmeester T, et al. Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 29: 2980-92. PMID 25854701 DOI: 10.1096/fj.14-262329 |
0.47 |
|
| 2014 |
Taymans JM, Baekelandt V. Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Frontiers in Genetics. 5: 382. PMID 25426138 DOI: 10.3389/fgene.2014.00382 |
0.548 |
|
| 2014 |
Göring S, Taymans JM, Baekelandt V, Schmidt B. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond Bioorganic and Medicinal Chemistry Letters. 24: 4630-4637. PMID 25219901 DOI: 10.1016/j.bmcl.2014.08.049 |
0.506 |
|
| 2014 |
Taymans JM, Baekelandt V, Harvey K. Regulation and targeting of enzymes mediating Parkinson's disease pathogenesis: focus on Parkinson's disease kinases, GTPases, and ATPases. Frontiers in Molecular Neuroscience. 7: 71. PMID 25120428 DOI: 10.3389/fnmol.2014.00071 |
0.454 |
|
| 2014 |
Reyniers L, Del Giudice MG, Civiero L, Belluzzi E, Lobbestael E, Beilina A, Arrigoni G, Derua R, Waelkens E, Li Y, Crosio C, Iaccarino C, Cookson MR, Baekelandt V, Greggio E, ... Taymans JM, et al. Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. Journal of Neurochemistry. PMID 24947832 DOI: 10.1111/Jnc.12798 |
0.406 |
|
| 2014 |
Vancraenenbroeck R, De Raeymaecker J, Lobbestael E, Gao F, De Maeyer M, Voet A, Baekelandt V, Taymans JM. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Frontiers in Molecular Neuroscience. 7: 51. PMID 24917786 DOI: 10.3389/fnmol.2014.00051 |
0.445 |
|
| 2014 |
Taymans JM. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease? Expert Opinion On Therapeutic Patents. 24: 727-730. PMID 24875782 DOI: 10.1517/13543776.2014.915945 |
0.492 |
|
| 2014 |
Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA, Olszewski M, ... ... Taymans JM, et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 111: 2626-31. PMID 24510904 DOI: 10.1073/Pnas.1318306111 |
0.539 |
|
| 2014 |
Schreurs S, Gerard M, Derua R, Waelkens E, Taymans JM, Baekelandt V, Engelborghs Y. In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants International Journal of Molecular Sciences. 15: 1040-1067. PMID 24434619 DOI: 10.3390/ijms15011040 |
0.407 |
|
| 2014 |
Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, Taymans JM, Urban MK, Sancho RM, Blanca RamÃrez M, Biskup S, Baekelandt V, Cai H, Cookson MR, Berwick DC, et al. A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. The Journal of Biological Chemistry. 289: 895-908. PMID 24275654 DOI: 10.1074/Jbc.M113.507913 |
0.366 |
|
| 2014 |
Vancraenenbroeck R, De Raeymaecker J, Lobbestael E, Gao F, De Maeyer M, Voet A, Baekelandt V, Taymans JM. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2 Frontiers in Molecular Neuroscience. 7. DOI: 10.3389/fnmol.2014.00051 |
0.445 |
|
| 2014 |
Taymans JM, Baekelandt V. Phosphatases of α-synuclein, LRRK2, and tau: Important players in the phosphorylation-dependent pathology of Parkinsonism Frontiers in Genetics. 5. DOI: 10.3389/fgene.2014.00382 |
0.547 |
|
| 2013 |
Taymans JM, Gao F, Baekelandt V. Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate Journal of Visualized Experiments. PMID 24084685 DOI: 10.3791/50523 |
0.387 |
|
| 2013 |
Lobbestael E, Zhao J, Rudenko IN, Beylina A, Gao F, Wetter J, Beullens M, Bollen M, Cookson MR, Baekelandt V, Nichols RJ, Taymans JM. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. The Biochemical Journal. 456: 119-28. PMID 23937259 DOI: 10.1042/Bj20121772 |
0.601 |
|
| 2013 |
Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, et al. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Human Molecular Genetics. 22: 608-20. PMID 23125283 DOI: 10.1093/Hmg/Dds470 |
0.414 |
|
| 2012 |
Lobbestael E, Baekelandt V, Taymans JM. Phosphorylation of LRRK2: From kinase to substrate Biochemical Society Transactions. 40: 1102-1110. PMID 22988873 DOI: 10.1042/BST20120128 |
0.591 |
|
| 2012 |
Taymans JM. The GTPase function of LRRK2 Biochemical Society Transactions. 40: 1063-1069. PMID 22988866 DOI: 10.1042/BST20120133 |
0.457 |
|
| 2012 |
Civiero L, Vancraenenbroeck R, Belluzzi E, Beilina A, Lobbestael E, Reyniers L, Gao F, Micetic I, De Maeyer M, Bubacco L, Baekelandt V, Cookson MR, Greggio E, Taymans JM. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. Plos One. 7: e43472. PMID 22952686 DOI: 10.1371/Journal.Pone.0043472 |
0.467 |
|
| 2012 |
Vancraenenbroeck R, Lobbestael E, Weeks SD, Strelkov SV, Baekelandt V, Taymans JM, De Maeyer M. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2 Biochimica Et Biophysica Acta - Proteins and Proteomics. 1824: 450-460. PMID 22251894 DOI: 10.1016/j.bbapap.2011.12.009 |
0.342 |
|
| 2011 |
Taymans JM, Vancraenenbroeck R, Ollikainen P, Beilina A, Lobbestael E, De Maeyer M, Baekelandt V, Cookson MR. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. Plos One. 6: e23207. PMID 21858031 DOI: 10.1371/Journal.Pone.0023207 |
0.441 |
|
| 2011 |
Vancraenenbroeck R, Lobbestael E, De Maeyer M, Baekelandt V, Taymans JM. Kinases as targets for Parkinson's disease: From genetics to therapy Cns and Neurological Disorders - Drug Targets. 10: 724-740. PMID 21838679 |
0.533 |
|
| 2011 |
Daniëls V, Baekelandt V, Taymans JM. On the road to leucine-rich repeat kinase 2 signalling: Evidence from cellular and in vivo studies Neurosignals. 19: 1-15. PMID 21430363 DOI: 10.1159/000324488 |
0.533 |
|
| 2011 |
Daniëls V, Vancraenenbroeck R, Law BM, Greggio E, Lobbestael E, Gao F, De Maeyer M, Cookson MR, Harvey K, Baekelandt V, Taymans JM. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. Journal of Neurochemistry. 116: 304-15. PMID 21073465 DOI: 10.1111/J.1471-4159.2010.07105.X |
0.336 |
|
| 2010 |
Taymans JM, Cookson MR. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 32: 227-35. PMID 20127702 DOI: 10.1002/Bies.200900163 |
0.511 |
|
| 2010 |
Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, Taymans JM, Wolozin B, Cookson MR. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. Plos One. 5: e8730. PMID 20090955 DOI: 10.1371/Journal.Pone.0008730 |
0.459 |
|
| 2009 |
Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 13971-80. PMID 19890007 DOI: 10.1523/Jneurosci.3799-09.2009 |
0.372 |
|
| 2009 |
Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, Beilina A, Sun P, Deng J, Jaffe H, Baekelandt V, Merchant K, Cookson MR. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochemical and Biophysical Research Communications. 389: 449-54. PMID 19733152 DOI: 10.1016/J.Bbrc.2009.08.163 |
0.499 |
|
| 2008 |
Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniëls V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. The Journal of Biological Chemistry. 283: 16906-14. PMID 18397888 DOI: 10.1074/Jbc.M708718200 |
0.506 |
|
| 2006 |
Taymans JM, Van Den Haute C, Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain Journal of Neurochemistry. 98: 951-961. PMID 16771836 DOI: 10.1111/j.1471-4159.2006.03919.x |
0.326 |
|
| Show low-probability matches. |